The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Bobkova M.R.

D.I. Ivanovsky Institute of Virology, Honorary Acad. N.F. Gamaleya Federal Research Centre for Epidemiology and Microbiology, Ministry of Health of Russia, Moscow, Russia

Genetic diversity of human immunodeficiency viruses and antiretroviral therapy

Authors:

Bobkova M.R.

More about the authors

Journal: Therapeutic Archive. 2016;88(11): 103‑111

DOI: 10.17116/terarkh20168811103-111

Read: 5633 times

Download PDF (RU)
Contact the author
Table of contents

GENETIC DIVERSITY OF HUMAN IMMUNODEFICIENCY VIRUSES AND ANTIRETROVIRAL THERAPY
GENETIC DIVERSITY OF HUMAN IMMUNODEFICIENCY VIRUSES AND ANTIRETROVIRAL THERAPY

To cite this article:

Bobkova MR. Genetic diversity of human immunodeficiency viruses and antiretroviral therapy. Therapeutic Archive. 2016;88(11):103‑111. (In Russ.)
https://doi.org/10.17116/terarkh20168811103-111

МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Personality profile caused by epilepsy acco­rding to the «Big Five» model. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(10):16-21
Genome instability of the cholera agent: role in the evolution of pathogenicity, drug resi­stance and adaptation to a changing envi­ronment. Mole­cular Gene­tics, Microbiology and Viro­logy. 2025;(2):3-13
Abstract:

The lecture is devoted to the analysis of the state-of-the-art of the impact of genetic diversity of human immunodeficiency (HIV) viruses on the pattern of infection and the efficiency of antiretroviral therapy (ART). It provides brief information on the origin and evolution of HIV and on the current classification of their genetic variants. The molecular epidemiological situation of HIV infection in Russia and nearby states and the major molecular HIV variants that are dominant in these countries, as well as their origin and prevalence trends are characterized. How the diversity of HIV can affect the efficiency of diagnosis, the transmission of the virus, and the pattern of HIV pathogenesis are briefly reviewed. The comparative data available in the world’s scientific literature on these topics are given. More detailed attention is given to the possible causes of varying therapeutic effects against different HIV subtypes, as well as to the specific features of the formation and phenotyping manifestation of ART drug resistance mutations. There is evidence for the necessity of forming a unified follow-up system for treated HIV-infected patients during ART scaling, including in an effort to evaluate the impact of the specific features of the HIV genome on the efficiency of treatment regimens used in Russia.

Keywords:

HIV
genetic variants
antiretroviral therapy
drug resistance

Authors:

Bobkova M.R.

D.I. Ivanovsky Institute of Virology, Honorary Acad. N.F. Gamaleya Federal Research Centre for Epidemiology and Microbiology, Ministry of Health of Russia, Moscow, Russia

Close metadata

References:

  1. Hemelaar J. The origin and diversity of the HIV-1 pandemic. Trends mol med. 2012;18(3):182-192. doi:10.1016/j.molmed.2011.12.001
  2. Korber B, Gaschen B, Yusim K, Thakallapally R, Kesmir C, Detours V. Evolutionary and immunological implications of contemporary HIV-1 variation. Br med bull. 2001;58:19-42.
  3. Ndung'u T, Weiss RA. On HIV diversity. AIDS (London, England). 2012;26(10):1255-1260. doi:10.1097/QAD.0b013e32835461b5
  4. Vuilleumier S, Bonhoeffer S. Contribution of recombination to the evolutionary history of HIV. Cur Opin HIV AIDS. 2015;10(2):84-89. doi:10.1097/COH.0000000000000137
  5. Sharp PM, Hahn BH. Origins of HIV and the AIDS pandemic. Cold Spring Harbor Perspectives Med.. 2011;1(1):a006841. doi:10.1101/cshperspect.a006841
  6. Bártolo I, Taveira N. HIV-1 Diversity and Its Implications in Diagnosis, Transmission, Disease Progression, and Antiretroviral Therapy. In: Caliskan M, ed. Genetic Diversity in Microorganisms. InTech; 2012.
  7. Maljkovic Berry I, Ribeiro R, Kothari M, Athreya G, Daniels M, Lee HY, Bruno W, Leitner T. Unequal evolutionary rates in the human immunodeficiency virus type 1 (HIV-1) pandemic: the evolutionary rate of HIV-1 slows down when the epidemic rate increases. J Virol. 2007;81(19):10625-10635. doi:10.1128/JVI.00985-07
  8. Eberle J, Gurtler L. HIV types, groups, subtypes and recombinant forms: errors in replication, selection pressure and quasispecies. Intervirology. 2012;55(2):79-83. doi:10.1159/000331993
  9. Peeters M, D'Arc M, Delaporte E. Origin and diversity of human retroviruses. AIDS Rev. 2014;16(1):23-34.
  10. Santoro MM, Perno CF. HIV-1 Genetic Variability and Clinical Implications. ISRN Microbiol. 2013;2013:481314. doi:10.1155/2013/481314
  11. Diez-Fuertes F, Cabello M, Thomson MM. Bayesian phylogeographic analyses clarify the origin of the HIV-1 subtype A variant circulating in former Soviet Union's countries. MEEGID. 2015;33:197-205. doi:10.1016/j.meegid.2015.05.003
  12. Bobkova M. Current status of HIV-1 diversity and drug resistance monitoring in the former USSR. AIDS Rev. 2013;15(4):204-212.
  13. Bobkov AF, Kazennova EV, Selimova LM, Khanina TA, Ryabov GS, Bobkova MR, Sukhanova AL, Kravchenko AV, Ladnaya NN, Weber JN, Pokrovsky VV. Temporal trends in the HIV-1 epidemic in Russia: predominance of subtype A. J Med Virol. 2004;74(2):191-196. doi:10.1002/jmv.20177
  14. Bobkova M, Buravtsova E, Sukhanova A, Ol'khovskii I, Bobkov A, Pokrovskii V. [Use of test-system Amplicor HIV-1 for HIV-infection diagnosis in newborn in Russia — first results (2001—2002)]. Klinicheskaia laboratornaia diagnostika. 2003;6:49-53. (In Russ.)
  15. Bogh M, Machuca R, Gerstoft J, Pedersen C, Obel N, Kvinesdal B, Nielsen H, Nielsen C. Subtype-specific problems with qualitative Amplicor HIV-1 DNA PCR test. J Clin Virol. 2001;20(3):149-153.
  16. Obaro SK, Losikoff P, Harwell J, Pugatch D. Failure of serial human immunodeficiency virus type 1 DNA polymerase chain reactions to identify human immunodeficiency virus type 1 clade A/G. Pediatr Infect Dis J. 2005;24(2):183-184.
  17. Luft LM, Gill MJ, Church DL. HIV-1 viral diversity and its implications for viral load testing: review of current platforms. International journal of infectious diseases: IJID. 2011;15(10):e661-670. doi:10.1016/j.ijid.2011.05.013
  18. Hudgens MG, Longini IM, Jr., Vanichseni S, Hu DJ, Kitayaporn D, Mock PA, Halloran ME, Satten GA, Choopanya K, Mastro TD. Subtype-specific transmission probabilities for human immunodeficiency virus type 1 among injecting drug users in Bangkok, Thailand. Am J Epidemiol. 2002;155(2):159-168.
  19. Kiwanuka N, Laeyendecker O, Quinn TC, Wawer MJ, Shepherd J, Robb M, Kigozi G, Kagaayi J, Serwadda D, Makumbi FE, Reynolds SJ, Gray RH. HIV-1 subtypes and differences in heterosexual HIV transmission among HIV-discordant couples in Rakai, Uganda. AIDS (London, England). 2009;23(18):2479-2484. doi:10.1097/QAD.0b013e328330cc08
  20. Huang W, Eshleman SH, Toma J, Fransen S, Stawiski E, Paxinos EE, Whitcomb JM, Young AM, Donnell D, Mmiro F, Musoke P, Guay LA, Jackson JB, Parkin NT, Petropoulos CJ. Coreceptor tropism in human immunodeficiency virus type 1 subtype D: high prevalence of CXCR4 tropism and heterogeneous composition of viral populations. J virol. 2007;81(15):7885-7893. doi:10.1128/JVI.00218-07
  21. Yang C, Li M, Newman RD, Shi YP, Ayisi J, van Eijk AM, Otieno J, Misore AO, Steketee RW, Nahlen BL, Lal RB. Genetic diversity of HIV-1 in western Kenya: subtype-specific differences in mother-to-child transmission. AIDS (London, England). 2003;17(11):1667-1674. doi:10.1097/01.aids.0000060412.18106.d4
  22. John-Stewart GC, Nduati RW, Rousseau CM, Mbori-Ngacha DA, Richardson BA, Rainwater S, Panteleeff DD, Overbaugh J. Subtype C Is associated with increased vaginal shedding of HIV-1. Journal Infect Dis. 2005;192(3):492-496. doi:10.1086/431514
  23. Martinez AM, Hora VP, Martinez AL, Mendoza-Sassi R, Von Groll A, Soares EA, D'Avila N, Silveira J, Leal RG, Tanuri A, Soares MA, Unit HA. Determinants of HIV-1 mother-to-child transmission in Southern Brazil. Anais da Academia Brasileira de Ciencias. 2006;78(1):113-121. doi:10.1590/s0001-37652006000100011
  24. Attia S, Egger M, Muller M, Zwahlen M, Low N. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS (London, England). 2009;23(11):1397-1404. doi:10.1097/QAD.0b013e32832b7dca
  25. Easterbrook PJ, Smith M, Mullen J, O'Shea S, Chrystie I, de Ruiter A, Tatt ID, Geretti AM, Zuckerman M. Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy. J Int AIDS Society. 2010;13:4. doi:10.1186/1758-2652-13-4
  26. Pant Pai N, Shivkumar S, Cajas JM. Does genetic diversity of HIV-1 non-B subtypes differentially impact disease progression in treatment-naive HIV-1-infected individuals? A systematic review of evidence: 1996—2010. J Acquired Immune Deficiency Syndromes.. 2012;59(4):382-328. doi:10.1097/QAI.0b013e31824a0628
  27. Sacktor N, Nakasujja N, Skolasky RL, Rezapour M, Robertson K, Musisi S, Katabira E, Ronald A, Clifford DB, Laeyendecker O, Quinn TC. HIV subtype D is associated with dementia, compared with subtype A, in immunosuppressed individuals at risk of cognitive impairment in Kampala, Uganda. Clin Infect Dis. 2009;49(5):780-786. doi:10.1086/605284
  28. Rao VR, Sas AR, Eugenin EA, Siddappa NB, Bimonte-Nelson H, Berman JW, Ranga U, Tyor WR, Prasad VR. HIV-1 clade-specific differences in the induction of neuropathogenesis. J Neuroscie. 2008;28(40):10010-10016. doi:10.1523/JNEUROSCI.2955-08.2008
  29. Bartolo I, Abecasis AB, Borrego P, Barroso H, McCutchan F, Gomes P, Camacho R, Taveira N. Origin and epidemiological history of HIV-1 CRF14_BG. PloS ONE. 2011;6(9):e24130. doi:10.1371/journal.pone.0024130
  30. Kiwanuka N, Laeyendecker O, Robb M, Kigozi G, Arroyo M, McCutchan F, Eller LA, Eller M, Makumbi F, Birx D, Wabwire-Mangen F, Serwadda D, Sewankambo NK, Quinn TC, Wawer M, Gray R. Effect of human immunodeficiency virus Type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection. J Infect Dis. 2008;197(5):707-713. doi:10.1086/527416
  31. De Wit S, Boulme R, Poll B, Schmit JC, Clumeck N. Viral load and CD4 cell response to protease inhibitor-containing regimens in subtype B versus non-B treatment-naive HIV-1 patients. AIDS (London, England). 2004;18(17):2330-2331.
  32. Frater AJ, Dunn DT, Beardall AJ, Ariyoshi K, Clarke JR, McClure MO, Weber JN. Comparative response of African HIV-1-infected individuals to highly active antiretroviral therapy. AIDS (London, England). 2002;16(8):1139-1146.
  33. Geretti AM, Harrison L, Green H, Sabin C, Hill T, Fearnhill E, Pillay D, Dunn D, Resistance UKCGoHD. Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy. Clin infect dis. 2009;48(9):1296-1305. doi:10.1086/598502
  34. Scherrer AU, Ledergerber B, von Wyl V, Boni J, Yerly S, Klimkait T, Burgisser P, Rauch A, Hirschel B, Cavassini M, Elzi L, Vernazza PL, Bernasconi E, Held L, Gunthard HF, Swiss HIVCS. Improved virological outcome in White patients infected with HIV-1 non-B subtypes compared to subtype B. Clin Infect Dis. 2011;53(11):1143-1152. doi:10.1093/cid/cir669
  35. Grossman Z, Schapiro JM, Levy I, Elbirt D, Chowers M, Riesenberg K, Olstein-Pops K, Shahar E, Istomin V, Asher I, Gottessman BS, Shemer Y, Elinav H, Hassoun G, Rosenberg S, Averbuch D, Machleb-Guri K, Kra-Oz Z, Radian-Sade S, Rudich H, Ram D, Maayan S, Agmon-Levin N, Sthoeger Z. Comparable long-term efficacy of Lopinavir/Ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. PloS ONE. 2014;9(1):e86239. doi:10.1371/journal.pone.0086239
  36. Rockstroh JK, Teppler H, Zhao J, Sklar P, Miller MD, Harvey CM, Strohmaier KM, Leavitt RY, Nguyen BY. Clinical efficacy of raltegravir against B and non-B subtype HIV-1 in phase III clinical studies. AIDS (London, England). 2011;25(11):1365-1369. doi:10.1097/QAD.0b013e328348065a
  37. Vingerhoets J, Azijn H, Tambuyzer L, Dierynck I, De Meyer S, Rimsky L, Nijs S, De Smedt G, de Bethune MP, Picchio G. Short communication: activity of etravirine on different HIV type 1 subtypes: in vitro susceptibility in treatment-naive patients and week 48 pooled DUET study data. AIDS Res Hum Retrovir. 2010;26(6):621-624. doi:10.1089/aid.2009.0239
  38. Dierynck I, De Meyer S, Lathouwers E, Vanden Abeele C, Van De Casteele T, Spinosa-Guzman S, de Bethune MP, Picchio G. In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients. Antiviral ther. 2010;15(8):1161-1169. doi:10.3851/IMP1697
  39. Gatell JM. Antiretroviral therapy for HIV: do subtypes matter? Clin Infect Dis. 2011;53(11):1153-1155. doi:10.1093/cid/cir686
  40. Tuaillon E, Gueudin M, Lemee V, Gueit I, Roques P, Corrigan GE, Plantier JC, Simon F, Braun J. Phenotypic susceptibility to nonnucleoside inhibitors of virion-associated reverse transcriptase from different HIV types and groups. J AIDS. 2004;37(5):1543-1549.
  41. Ren J, Bird LE, Chamberlain PP, Stewart-Jones GB, Stuart DI, Stammers DK. Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors. Proceedings of the National Academy of Sciences of the United States of America. 2002;99(22):14410-14415. doi:10.1073/pnas.222366699
  42. Kinomoto M, Appiah-Opong R, Brandful JA, Yokoyama M, Nii-Trebi N, Ugly-Kwame E, Sato H, Ofori-Adjei D, Kurata T, Barre-Sinoussi F, Sata T, Tokunaga K. HIV-1 proteases from drug-naive West African patients are differentially less susceptible to protease inhibitors. Clin Infect Dis. 2005;41(2):243-251. doi:10.1086/431197
  43. Lessells RJ, Katzenstein DK, de Oliveira T. Are subtype differences important in HIV drug resistance? Cur Opin Virol. 2012;2(5):636-643. doi:10.1016/j.coviro.2012.08.006
  44. Rhee SY, Sankaran K, Varghese V, Winters M, Hurt CB, Eron JJ, Parkin N, Holmes SP, Holodniy M, Shafer RW. HIV-1 Protease, Reverse Transcriptase, and Integrase Variation. J Virol. 2016; [Epub ahead of print]. doi:10.1128/JVI.00495-16
  45. Bobkova M. HIV drug resistance. Мoscow: Chelovek; 2014. (In Russ.)
  46. Scherrer AU, Ledergerber B, von Wyl V, Boni J, Yerly S, Klimkait T, Cellerai C, Furrer H, Calmy A, Cavassini M, Elzi L, Vernazza PL, Bernasconi E, Gunthard HF, Swiss HIVCS. Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patients. PloS ONE. 2012;7(6):e37983. doi:10.1371/journal.pone.0037983
  47. Mackie NE, Dunn DT, Dolling D, Garvey L, Harrison L, Fearnhill E, Tilston P, Sabin C, Geretti AM, Database UHDR, study UC. The impact of HIV-1 reverse transcriptase polymorphisms on responses to first-line nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-1-infected adults. AIDS (London, England). 2013;27(14):2245-2253. doi:10.1097/QAD.0b013e3283636179
  48. Brenner BG, Coutsinos D. The K65R mutation in HIV-1 reverse transcriptase: genetic barriers, resistance profile and clinical implications. HIV Ther. 2009;3(6):583-594. doi:10.2217/hiv.09.40
  49. Kolomeets AN, Varghese V, Lemey P, Bobkova MR, Shafer RW. A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. AIDS (London, England). 2014;28(17):F1-8. doi:10.1097/QAD.0000000000000485
  50. Lai MT, Lu M, Felock PJ, Hrin RC, Wang YJ, Yan Y, Munshi S, McGaughey GB, Tynebor RM, Tucker TJ, Williams TM, Grobler JA, Hazuda DJ, McKenna PM, Miller MD. Distinct mutation pathways of non-subtype B HIV-1 during in vitro resistance selection with nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother. 2010;54(11):4812-4824. doi:10.1128/AAC.00829-10
  51. Santos AF, Tebit DM, Lalonde MS, Abecasis AB, Ratcliff A, Camacho RJ, Diaz RS, Herchenroder O, Soares MA, Arts EJ. Effect of natural polymorphisms in the HIV-1 CRF02_AG protease on protease inhibitor hypersusceptibility. Antimicrob Agents Chemother. 2012;56(5):2719-2725. doi:10.1128/AAC.06079-11
  52. Martinez-Cajas JL, Wainberg MA, Oliveira M, Asahchop EL, Doualla-Bell F, Lisovsky I, Moisi D, Mendelson E, Grossman Z, Brenner BG. The role of polymorphisms at position 89 in the HIV-1 protease gene in the development of drug resistance to HIV-1 protease inhibitors. Antimicrob Agents Chemother. 2012;67(4):988-994. doi:10.1093/jac/dkr582
  53. Bar-Magen T, Donahue DA, McDonough EI, Kuhl BD, Faltenbacher VH, Xu H, Michaud V, Sloan RD, Wainberg MA. HIV-1 subtype B and C integrase enzymes exhibit differential patterns of resistance to integrase inhibitors in biochemical assays. AIDS (London, England). 2010;24(14):2171-2179. doi:10.1097/QAD.0b013e32833cf265
  54. Coutsinos D, Invernizzi CF, Xu H, Brenner BG, Wainberg MA. Factors affecting template usage in the development of K65R resistance in subtype C variants of HIV type-1. Antiviral Chem Chemother. 2010;20(3):117-131. doi:10.3851/IMP1443
  55. Grossman Z, Paxinos EE, Averbuch D, Maayan S, Parkin NT, Engelhard D, Lorber M, Istomin V, Shaked Y, Mendelson E, Ram D, Petropoulos CJ, Schapiro JM. Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir. Antimicrob Agents Chemother. 2004;48(6):2159-2165. doi:10.1128/AAC.48.6.2159-2165.2004
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.